Soleno Therapeutics, Inc. (SLNO)
$53.01+0.00%Close
BUYBULL · day 11
Key stats
- Market cap
- $2.8B
- Beta
- -2.22
- P/E (TTM)
- 27.09
- 1W
- +0.13%
- 1M
- +0.44%
- vs SPY 1W
- +0.27%
- vs SPY 1M
- -2.07%
Industry peers
FMP comparable companies · ranked by market cap
- APGEBUYApogee Therapeutics, Inc.$8.4BBULLQ 60$135.07-0.01%
- PRAXSELLPraxis Precision Medicines, Inc.$7.8BCRISISQ 11$280.14-3.20%
- CNTACentessa Pharmaceuticals plc$6.3B$40.50
- MIRMSELLMirum Pharmaceuticals, Inc.$4.8BCRISISQ 37$79.25-7.48%
- XENESELLXenon Pharmaceuticals Inc.$3.5BCRISISQ 22$36.57-3.88%
- CELCSELLCelcuity Inc.$3.5BCRISISQ 26$71.25-4.04%
- VKTXSELLViking Therapeutics, Inc.$3.3BCRISISQ 22$28.38-5.96%
- DYNSELLDyne Therapeutics, Inc.$2.9BCRISISQ 3$15.40-4.14%
- AAPGSELLAscentage Pharma Group International$1.5BCRISISQ 5$16.09-1.63%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.4BRECOVERYQ -6$14.46-2.48%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 64
- VALUE
- 19
- GROWTH
- 61
- GARP
- 94
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC13.7%
REV YoY-
ROE22.9%
EPS YoY-
ROA15.8%
GROSS99
OP31
NET34
[VALUATION]
P/E TTM27.09
P/E FWD9.76
SECTOR PE20.34
INDUSTRY PE13.84
P/B5.57
P/FCF-
EV/EBITDA24.62
EV/EBIT-
PEG0.30
FCF YIELD-
RISK
INT COV-
D/E0.89
ALTMAN Z-
CURR RATIO5.62
ND/EBITDA-
BETA-2.22
Company news
FAQ
- What is LOPJLB’s current signal on SLNO?
- LOPJLB’s latest quantitative signal on Soleno Therapeutics, Inc. (SLNO) is BUY in a BULL regime. Signals are updated daily.
- What market regime is SLNO in?
- Soleno Therapeutics, Inc. (SLNO) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Soleno Therapeutics, Inc. (SLNO) do?
- Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III…